Aminoglycosides

Antimicrobial Pharmacodynamics in Theory and Clinical Practice, Second Edition

Volumn , Issue , 2007, Pages 147-175

  Kim, Myo Kyoung ^a   Nicolau, David P ^b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85122646653     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (184)

1. Kondo S, Iinuma K, Yamamoto H, Ikeda Y, Maeda K. Letter: synthesis of (S)-4-amino-2-hydroxybutyryl derivatives of 3', 4'-dideoxykanamycin B and their antibacterial activities. J Antibiot (Tokyo) 1973; 26(11):705-707.
2. Fillastre JP, Leroy A, Humbert G, Moulin B, Bernadet P, Josse S. Pharmacokinetics of habekacin in patients with chronic renal insufficiency. Pathol Biol (Paris) 1987; 35(5 Pt 2):739-741.
3. Cundliffe E. Antibiotics and prokaryotic ribosomes: action, interaction and resistance. In: Hill WE, Dahlberg A, Garrett RA, Moore PB, Schlessinger D, Warner JR, eds. Ribosomes. Washington, D.C.: American Society for Microbiology, 1990:479-490.
4. Davies JE. Resistance to aminoglycosides: mechanisms and frequency. Rev Infect Dis 1983; 5:S261-S266.
5. Hancock REW. Aminoglycoside uptake and mode of action with special reference to streptomycin and gentamicin. J Antimicrob Chemother 1981; 8:249-276.
6. Hancock REW, Farmer SW, Li Z, Poole K. Interaction of aminoglycosides with the outer membranes and purified lipopolysaccharide and OmpF porin of Escherichia coli. Antimicrob Agents Chemother 1991; 35:1309-1314.
7. Gale EF, Cundliffe E, Reynolds PE, Richmond MH, Waring MJ. The Molecular Basis of Antibiotic Action. London: John Wiley & Sons, 1981.
8. Davis BD, Tai PC, Wallace BJ. Complex interactions of antibiotics with the ribosome. In: Nomura M, Tissieres A, Lengyel P, eds. Ribosomes. New York: Cold Spring Harbor Laboratory, 1974:771-789.
9. Gorini L. Streptomycin and misreading of the genetic code. In: Nomura M, Tissieres A, Lengyel P, eds. Ribosomes. New York: Cold Spring Harbor Laboratory, 1974: 791-803.
10. Ruusala T, Kurland CG. Streptomycin preferentially perturbs ribosomal proofreading. Mol Gen 1984; 198:100-104.
11. Matsunaga K, Yamaki H, Nishimura T, Tanaka N. Inhibition of DNA replication initiation by aminoglycoside antibiotics. Antimicrob Agents Chemother 1986; 30: 468-474.
12. Arya DP, Xue L, Willis B. Aminoglycoside (neomycin) preference is for A-form nucleic acids, not just RNA: results from a competition dialysis study. J Am Chem Soc 2003; 125(34):10148-10149.
13. Fujimura S, Tokue Y, Takahashi H, et al. Novel arbekacin- and amikacin-modifying enzyme of methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 2000; 190(2):299-303.
14. Matsuo H, Kobayashi M, Kumagai T, Kuwabara M, Sugiyama M. Molecular mechanism for the enhancement of arbekacin resistance in a methicillin-resistant Staphylococcus aureus. FEBS Lett 2003; 546(2-3):401-406.
15. Tanaka N, Matsunaga K, Hirata A, Matsuhisa Y, Nishimura T. Mechanism of action of habekacin, a novel amino acid-containing aminoglycoside antibiotic. Antimicrob Agents Chemother 1983; 24(5):797-802.
16. Akins RL, Rybak MJ. in vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 2000; 44(7):1925-1929.
17. Axelrod HR, Kim JS, Longley CB, et al. Intestinal transport of gentamicin with a novel, glycosteroid drug transport agent. Pharm Res 1998; 15(12):1876-1881.
18. Swenson C, Curatolo WJ. Means to enhance penetration. Adv Drug Deliv Rev 1992; 8:39-92.
19. Rama Prasad YV, Eaimtrakarn S, Ishida M, et al. Evaluation of oral formulations of gentamicin containing labrasol in beagle dogs. Int J Pharm 2003; 268(1-2):13-21.
20. Ross BP, DeCruz SE, Lynch TB, Davis-Goff K, Toth I. Design, synthesis, and evaluation of a liposaccharide drug delivery agent: application to the gastrointestinal absorption of gentamicin. J Med Chem 2004; 47(5):1251-1258.
21. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother 1991; 27(suppl C):41-47.
22. Santre C, Georges H, Jacquier JM, et al. Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. Antimicrob Agents Chemother 1995; 39:264-267.
23. Valcke YJ, Vogelaers DP, Colardyn FA, Pauwels RA. Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 1992; 101:1028-1032.
24. Zarowitz BJ, Robert S, Peterson EL. Prediction of glomerular filtration rate using aminoglycoside clearance in critically ill medical patients. Ann Pharmacother 1992; 26:1205-1210.
25. Begg EJ, Peddie BA, Chambers ST, Boswell DR. Comparison of gentamicin dosing regimens using an in-vitro model. J Antimicrob Chemother 1992; 29:427-433.
26. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; (suppl 74):63-70.
27. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluor-oquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37:483-490.
28. Dudley MN. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991; 91(suppl 6A):45S-50S.
29. Davis BD. Mechanism of the bactericidal action of the aminoglycosides. Microbiol Rev 1987; 51:341-350.
30. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotic: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990; 11: 319-326.
31. Blaser J, Stone B, Groner M, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agent Chemother 1987; 31:1054-1060.
32. Leggett JE, Ebert S, Fantin B, Craig WA. Comparative dose-effect relationships at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scan J Infect Dis 1991; 74:179-184.
33. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77:657-662.
34. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984; 149: 443-448.
35. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99.
36. Deziel-Evans L, Murphy J, Job M. Correlation of pharmacokinetic indices with therapeutic outcomes in patients receiving aminoglycoside. Clin Pharm 1986; 5: 319-324.
37. Keating MF, Bodey GP, Valdivieso M, Rodriguez V. A randomized comparative trial of three aminoglycosides-comparison of continuous infusions of gentamicin, amika-cin, and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine 1979; 58:159-170.
38. Williams PJ, Hull JH, Sarubbi FA, Rogers JF, Wargin WA. Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin. J Clin Pharmacol 1986; 26:79-86.
39. Fiala M, Chatterjee SN. Antibiotic blood concentrations in patients successfully treated with tobramycin. Postgrad Med 1981; 57:548-551.
40. Berirtzoglou E, Golegou S, Savvaidis I, Bezirtzoglou C, Beris A, Xenakis T. A relationship between serum gentamicin concentrations and minimal inhibitor concentration. Drugs Exp Clin Res 1996; 22:57-60.
41. Binder L, Schiel X, Binder C, et al. Clinical outcome and economic impact of aminoglycoside peak concentrations in febrile immunocompromised patients with hematologic malignancies. Clin Chem 1998; 44:408-414.
42. Anderson ET, Young LS, Hewitt WL. Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia. Am J Med 1976; 61:493-497.
43. Noone P, Parsons TMC, Pattison JR, Slack RCB, Garfield-Davies D, Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gramnegative sepsis. Br Med J 1974; 1:477-481.
44. Reymann MT, Bradac JA, Cobbs CG, Dismukes WE. Correlation of aminoglycoside dosage with serum concentrations during therapy of serious gram-negative bacillary disease. Antimicrob Agent Chemother 1979; 16:13353-13361.
45. Kashuba ADM, Bertino JS Jr, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gramnegative organism. Antimicrob Agent Chemother 1998; 42:1842-1844.
46. Kashuba ADM, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agent Chemother 1999; 43:1623-1629.
47. Craig W, Gunmundsson S. Postantibiotic effect. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 4th ed. Baltimore, Philadelphia: Williams & Wilkins, 1987:296-329.
48. Zhanel G, Hoban D, Harding G. The postantibiotic effect: a review of in-vitro and in vivo data. Ann Pharmacother 1991; 25:153-163.
49. Bundtzen R, Gerber A, Cohn D, et al. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981; 3:28-37.
50. Vogelman B, Gudmundsson S, Turnidge J, et al. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988; 157:287-298.
51. Hessen M, Pitsakis P, Levison M. Postantibiotic effect of penicillin plus gentamicin versus Enterococcus faecalis in vitro and in vivo. Antimicrob Agent Chemother 1989; 33:608-611.
52. McGrath B, Marchbanks C, Gilbert D, et al. In vitro postantibiotic effect following exposure to imipenem, temafloxacin, and tobramycin. Antimicrob Agent Chemother 1993; 37:1723-1725.
53. Vogelman B, Craig W. Postantibiotic effects. J Antimicrob Chemother 1985; 15(suppl A):37-46.
54. Odenholt-Tornqvist I. Pharmacodynamics of beta-lactam antibiotics: studies on the paradoxical effect and postantibiotic effects in vitro and in an animal model. Scand J Infect Dis 1989; 58(S):1-55.
55. Craig W, Leggett K, Totsuka K, et al. Key pharmacokinetic parameters of antibiotic efficacy in experimental animal infections. J. Drug Dev 1998; 1(S3):7-15.
56. Dornbusch K, Henning C, Linden E. In-vitro activity of the new penems FCE 22101 and FCE 24362 alone or in combination with aminoglycosides against streptococci isolated from patients with endocarditis. J Antimicrob Chemother 1989; 23(suppl C): 109-117.
57. Fuursted K. Comparative killing activity and postantibiotic effect of streptomycin combined with ampicillin, ciprofloxacin, imipenem, piperacillin, or vancomycin against strains of Streptococcus faecalis and Streptococcus faecium. Chemother 1988; 34:229-234.
58. Winstanley T, Hastings J. Penicillin-aminoglycosides synergy and post-antibiotic effect for enterococci. JAC 1989; 23:189-199.
59. Gudmundsson S, Erlendsdottir H, Gottfredsson M, et al. The postantibiotic effect induced by antimicrobial combinations. Scand J Infect Dis 1991; 74:80-93.
60. Karlowsky J, Zhanel G, Davidson R, et al. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. J Antimicrob Chemother 1994; 33:937-947.
61. Karlowsky J, Zhanel G, Davidson R, et al. In vitro postantibiotic effects following multiple exposures of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth. Antimicrob Agent Chemother 1993; 37:1154-1157.
62. Li R, Zhu Z, Lee S, et al. Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa. Antimicrob Agent Chemother 1997; 41:1808-1811.
63. Rescott D, Nix D, Holden P, et al. Comparison of two methods for determining in vitro postantibiotic effects of three antibiotics on Escherichia coli. Antimicrob Agent Chemother 1998; 32:450-453.
64. Fuursted K. Postexposure factors influencing the duration of postantibiotic effect: significance of temperature, pH, cations, and oxygen tension. Antimicrob Agent Chemother 1997; 41:1693-1696.
65. Gudmundsson A, Erlendsdottir H, Gottfredsson M, et al. The impact of pH and cationic supplementation on in vitro postantibiotic effect. Antimicrob Agent Chemother 1991; 35:2617-2624.
66. Park MK, Myers R, Marzella L. Hyperoxia and prolongation of aminoglycoside-induced postantibiotic effect in Pseudomonas aeruginosa: role of reactive oxygen species. Antimicrob Agent Chemother 1993; 37:120-122.
67. Hanberger H, Nilsson L, Maller R, et al. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agent Chemother 1991; 35:1710-1716.
68. Cars O, Odenholt-Tornqvist I. The postantibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother 1993; 31(suppl D):159-166.
69. Craig W, Vogelman B. The postantibiotic effect. Ann Intern Med 1987; 106:900-902.
70. Gottfredsson M, Erlendsdottir H, Gudmundsson, et al. Different patterns of bacterial DNA synthesis during the postantibiotic effect. Antimicrob Agent Chemother 1995; 39:1314-1319.
71. Barmada S, Kohlhepp S, Leggett J, et al. Correlation of tobramycin-induced inhibition of protein synthesis with postantibiotic effect in Escherichia coli. Antimicrob Agent Chemother 1993; 37:2678-2683.
72. Minguez F, Izquierdo J, Caminero M, et al. In vivo postantibiotic effect of isepamicin and other aminoglycosides in a thigh infection model in neutropenic mice. Chemother 1992; 38:179-184.
73. Gudmundsson S, Einarsson S, Erlendsdottir H. The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model. J Antimicrob Chemother 1993; 31(suppl D):177-191.
74. Craig W, Redington J, Ebert S. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27(SC):29-40.
75. Hessen M, Pitsakis P, Levison M. Absence of a postantibiotic effect in experimental Pseudomonas endocarditis treated with imipenem, with or without gentamicin. J Infect Dis 1998; 158:542-548.
76. Craig W. Post-antibiotic effects in experimental infection model: relationship to in-vitro phenomena and to treatment of infection in man. J Antimicrob Chemother 1993; 31(suppl D):149-158.
77. Fantin B, Craig W. Factors affecting duration of in vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli. Antimicrob Agents Chemother 1991; 27:829-836.
78. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999; 43(4):727-737.
79. Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994; 38:1165-1168.
80. Daikos GL, Jackson GG, Lolans V, Livermore DM. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 1990; 162:414-420.
81. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglyco-side antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35:117-123.
82. Gerber AU, Vastola AP, Brandel J, Craig WA. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J Infect Dis 1982; 146:691-697.
83. Owens RC Jr., Banevicius MA, Nicolau DP, Nightingale CH, Quintiliani R. In vitro synergistic activities of tobramycin and selected /-lactams against 75 gram-negative clinical isolates. Antimicrob Agents Chemother 1997; 41:2586-2588.
84. Marangos MN, Nicolau DP, Quintiliani R, Nightingale CH. Influence of gentamicin dosing interval on the efficacy of penicillin containing regimens in experimental Enterococcus faecalis endocarditis. J Antimicrob Chemother 1997; 39:519-522.
85. Hallander HO, Donrbusch K, Gezelius L, Jacobson K, Karlsson I. Synergism between aminoglycosides and cephalosporins with anti-pseudomonal activity: interaction index and killing curve method. Antimicrob Agents Chemother 1982; 22:743-752.
86. Sandoval RM, Molitoris BA. Gentamicin traffics retrograde through the secretory pathway and is released in the cytosol via the endoplasmic reticulum. Am J Physiol Renal Physiol 2004; 286(4):F617-F624.
87. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991:35:399-405.
88. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39:650-655.
89. Govaerts PJ, Claes J, van de Heyning PH, Jorens PG, Marquet J, De Broe ME. Aminoglycoside-induced ototoxicity. Toxicol Lett 1990; 52(3):227-251.
90. Matz G, Rybak L, Roland PS, et al. Ototoxicity of ototopical antibiotic drops in humans. Otolaryngol Head Neck Surg 2004; 130(3 suppl):S79-S82.
91. Hutchin T, Cortopassi G. Proposed molecular and cellular mechanism for aminoglycoside ototoxicity. Antimicrob Agents Chemother 1994; 38:2517-2520.
92. Fausti SA, Henry JA, Scheffer HI, Olson DJ, Frey RH, McDonald WJ. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992; 165:1026-1032.
93. Federspil P. Drug-induced sudden hearing loss and vestibular disturbances. Adv Otorhinolaryngol 1981; 27:144-158.
94. Rakover Y, Keywan K, Rosen G. Safety of topical ear drops containing ototoxic antibiotics. J Otolaryngol 1997; 26(3):194-196.
95. Merifield DO, Parker NJ, Nicholson NC. Therapeutic management of chronic suppurative otitis media with otic drops. Otolaryngol Head Neck Surg 1993; 109(1): 77-82.
96. Welling DB, Forrest LA, Goll F 3rd. Safety of ototopical antibiotics. Laryngoscope 1995; 105(5 Pt 1):472-474.
97. Kaplan DM, Nedzelski JM, Al-Abidi A, Chen JM, Shipp DB. Hearing loss following intratympanic instillation of gentamicin for the treatment of unilateral Meniere's disease. J Otolaryngol 2002; 31(2):106-111.
98. Kaplan DM, Hehar SS, Bance ML, Rutka JA. Intentional ablation of vestibular function using commercially available topical gentamicin-betamethasone eardrops in patients with Meniere's disease: further evidence for topical eardrop ototoxicity. Laryngoscope 2002; 112(4):689-695.
99. Lange G, Maurer J, Mann W. Long-term results after interval therapy with intratym-panic gentamicin for Meniere's disease. Laryngoscope 2004; 114(1):102-105.
100. Rybak LP, Kelly T. Ototoxicity: bioprotective mechanisms. Curr Opin Otolaryngol Head Neck Surg 2003; 11(5):328-333.
101. Klemens JJ, Meech RP, Hughes LF, Somani S, Campbell KC. Antioxidant enzyme levels inversely covary with hearing loss after amikacin treatment. J Am Acad Audiol 2003; 14(3):134-143.
102. Matsui JI, Haque A, Huss D, et al. Caspase inhibitors promote vestibular hair cell survival and function after aminoglycoside treatment in vivo. J Neurosci 2003; 23(14):6111-6122.
103. Beaubien AR, Ormsby E, Bayne A, et al. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Antimicrob Agents Chemother 1991; 35:1070-1074.
104. Proctor L, Petty B, Lietman P, Thakor R, Glackin R, Shimizu H. A study of potential vestibulotoxicity effects of once daily versus thrice daily administration of tobramycin. Laryngoscope 1987; 97:1443-1449.
105. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43:1549-1555.
106. Garrison MW, Zaske DE, Rotschafer JC. Aminoglycosides: another perspective. DICP Ann Pharmacother 1990; 24:267-272.
107. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999; 43(5):1003-1012.
108. Moore RD, Smith CR, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100:352-357.
109. Sawyers CL, Moore RD, Lerner SA, Smith CR. A model for predicting nephrotoxicity with aminoglycosides. J Infect Dis 1986; 153:1062-1068.
110. Whelton A. Therapeutic initiatives for avoidance of aminoglycoside toxicity. J Clin Pharmacol 1985; 25:67-81.
111. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Nafziger AN. Incidence and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167:173-179.
112. Nodoushani M, Nicolau DP, Hitt CH, Quintiliani R, Nightingale CH. Evaluation of nephrotoxicity associated with once-daily aminoglycoside administration. J Pharm Tech 1997; 13:258-262.
113. Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food Chem Toxicol 2003; 41(11):1447-1452.
114. Maldonado PD, Barrera D, Medina-Campos ON, Hernandez-Pando R, Ibarra-Rubio ME, Pedraza-Chaverri J. Aged garlic extract attenuates gentamicin induced renal damage and oxidative stress in rats. Life Sci 2003; 73(20):2543-2556.
115. Parlakpinar H, Ozer MK, Sahna E, Vardi N, Cigremis Y, Acet A. Amikacin-induced acute renal injury in rats: protective role of melatonin. J Pineal Res 2003; 35(2):85-90.
116. Sohn EJ, Kang DG, Lee HS. Protective effects of glycyrrhizin on gentamicin-induced acute renal failure in rats. Pharmacol Toxicol 2003; 93(3):116-122.
117. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME. Once daily dosing decreases the accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45:22-27.
118. Murray KR, McKinnon PS, Mitrzyk B, Rybak MJ. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacother 1999; 19:1252-1260.
119. Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target concentration intervention-parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 2004; 58(1): 8-19.
120. Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents 2004; 23(3):291-295.
121. Rougier F, Claude D, Maurin M, et al. Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother 2003; 47(3):1010-1016.
122. Sarubbi FA Jr, Hull JH. Amikacin serum concentrations: prediction of levels and dosage guidelines. Ann Intern Med 1978; 89:612-618.
123. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976; 4:183-195.
124. Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977; 21:362-369.
125. Schumock GT, Raber SR, Crawford SY, Naderer OJ, Rodvold KA. National survey of once-daily dosing of aminoglycoside antibiotics. Pharmacother 1995; 15:201-209.
126. Chuck SK, Raber SR, Rodvold KA, Areff D. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis 2000; 30:433-439.
127. DeVries PJ, Verkooyen RP, Leguit P, Verbrugh HA. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990; 9:161-168.
128. Mauracher EH, Lau WY, Kartowisastro H, et al. Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections: a multicenter study in six Asian countries. Clin Ther 1989; 11:604-613.
129. Maller R, Ahrne H, Eilard T, et al. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. J Antimicrob Chemother 1991; 27(suppl C):121-128.
130. Maller R, Ahrne H, Holmen C, et al. Onceversus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. J Antimicrob Chemother 1993; 31:939-948.
131. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341:335-339.
132. Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993; 31:585-598.
133. TerBraak EW, DeVries PJ, Bouter KP, et al. Once-daily dosing regimen for aminogly-coside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89:58-66.
134. International Antimicrobial Therapy Cooperative Group of the EORTC. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119:584-593.
135. Beaucaire G, Leroy O, Beuscart C, et al. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 1991; 27(suppl C):91-103.
136. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections-a randomized clinical trial. J Antimicrob Chemother 1994; 33:823-835.
137. Galoe AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48:39-43.
138. Freeman CD, Strayer AH. Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacother 1996; 16:1093-1102.
139. Hatala R, Dinh T, Cook D. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124:717-725.
140. Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple doses of aminoglycosides: a meta-analysis. BMJ 1996; 312:338-345.
141. Munckhof WJ, Grayson JL, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given with once daily or as divided doses. J Antimicrob Chemother 1996; 37:645-663.
142. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminogly-cosides: a meta-analysis. Am J Health-Syst Pharm 1996; 53:1141-1150.
143. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24:786-795.
144. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809.
145. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocom-promised adults: a systematic review. Clin Infect Dis 1997; 24:810-815.
146. Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28:753-764.
147. Nicolau DP, Quintiliani R, Nightingale CH. Once-a-day aminoglycoside therapy. Report Ped Infect Dis 1997; 7:28.
148. Sung L, Dupuis LL, Bliss B, et al. Randomized controlled trial of once- versus thrice-daily tobramycin in febrile neutropenic children undergoing stem cell transplantation. J Natl Cancer Inst 2003; 95(24):1869-1877.
149. Mercado MC, Brodsky NL, McGuire MK, Hurt H. Extended interval dosing of gentamicin in preterm infants. Am J Perinatol 2004; 21(2):73-77.
150. Bhatt-Mehta V, Donn SM. Gentamicin pharmacokinetics in term newborn infants receiving high-frequency oscillatory ventilation or conventional mechanical ventilation: a case-controlled study. J Perinatol 2003; 23(7):559-562.
151. Dupuis LL, Sung L, Taylor T, et al. Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration. Pharmacotherapy 2004; 24(5):564-573.
152. Piekarczyk A, Kaminska E, Taljanski W, Sosonowska K, Poszwinska B, Rutkowska, M. Pharmacokinetics of netilmicin in neonates. Med Wieku Rozwoj 2003; 7(4 Pt 2):547-555.
153. English M, Mohammed S, Ross A, et al. A randomised, controlled trial of once daily and multi-dose daily gentamicin in young Kenyan infants. Arch Dis Child 2004; 89(7):665-669.
154. Botha JH, du Preez MJ, Adhikari M. Population pharmacokinetics of gentamicin in South African newborns. Eur J Clin Pharmacol 2003; 59(10):755-759.
155. Kosalaraksa P, Janthep P, Jirapradittha J, Taksaphan S, Kiatchoosakun P. Once versus twice daily dose of gentamicin therapy in Thai neonates. J Med Assoc Thai 2004; 87(4):372-376.
156. Knight JA, Davis EM, Manouilov K, Hoie EB. The effect of postnatal age on gentamicin pharmacokinetics in neonates. Pharmacotherapy 2003; 23(8):992-996.
157. Hansen A, Forbes P, Arnold A, O'Rourke E. Once-daily gentamicin dosing for the preterm and term newborn: proposal for a simple regimen that achieves target levels. J Perinatol 2003; 23(8):635-639.
158. Bourget P, Fernandez H, Delouis C, Taburet AM. Pharmacokinetics of tobramycin in pregnant women, safety and efficacy of a once-daily dose regimen. J Clin Pharm Ther 1991; 16:167-176.
159. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004; 114(1): e111-e118.
160. Demczar DJ, Nafziger AN, Bertino JS Jr. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 1997; 41:1115-1119.
161. Xuan D, Lu JF, Nicolau DP, Nightingale CH. Population pharmacokinetics study of tobramycin after once-daily dosing in hospitalized patients. Intern J Antimicrob Agents 2000; 15:185-191.
162. Konrad F, Wagner R, Neumeister B, Rommel H, Georgieff M. Studies on drug monitoring in thrice and once daily treatment with aminoglycosides. Intensive Care Med 1993; 19:215-220.
163. Gilbert DN, Bennett WM. Use of antimicrobial agents in renal failure. Infect Dis Clin North Am 1989; 3:517-531.
164. Prins JM, Koopmans RP, Buller HR, Kuijper EJ, Speelman P. Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Eur J Clin Microbiol Infect Dis 1995; 14:531-535.
165. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39:605-609.
166. Nicolau DP, Wu AHB, Finocchiaro S, et al. Once-daily aminoglycoside dosing: impact on requests for therapeutic drug monitoring. Therapeutic Drug Mon 1996; 18:263-266.
167. Hitt CM, Klepser ME, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacoeconomic impact of a once-daily aminoglycoside administration. Pharmacother 1997:17810-17814.
168. Parker SE, Davey PG. Once-daily aminoglycoside administration in gram-negative sepsis: economic and practical aspects. Pharmacoeconomics 1995; 7:393-402.
169. Klepser ME. Role of nebulized antibiotics for the treatment of respiratory infections. Curr Opin Infect Dis 2004; 17(2):109-112.
170. Flume P, Klepser ME. The rationale for aerosolized antibiotics. Pharmacotherapy 2002; 22(3 Pt 2):71S-79S.
171. Tiddens H. Inhaled antibiotics. Pediatr Pulmonol Suppl 2004; 26:92-94.
172. Cole PJ. The role of nebulized antibiotics in treating serious respiratory infections. J Chemother 2001; 13(4):354-362.
173. de Boer AH, Hagedoorn P, Frijlink HW. The choice of a compressor for the aerosolisa-tion of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser. Int J Pharm 2003; 268(1-2):59-69.
174. Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003; 63(22):2501-2520.
175. Eisenberg J, Pepe M, Williams-Warren J, et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest 1997; 111(4):955-962.
176. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122(1): 219-226.
177. Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001; 120(3 suppl):107S-113S.
178. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340(1):23-30.
179. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162(2 Pt 1):481-485.
180. Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003; 124(1):360-366.
181. Al-Kassas R. Design and in vitro evaluation of gentamicin-Eudragit microspheres intended for intra-ocular administration. J Microencapsul 2004; 21(1):71-81.
182. Sterling GJ, Crawford S, Potter JH, Koerbin G, Crawford R. The pharmacokinetics of simplex-tobramycin bone cement. J Bone Joint Surg Br 2003; 85(5):646-649.
183. Fletcher MD, Spencer RF, Langkamer VG, Lovering AM. Gentamicin concentrations in diagnostic aspirates from 25 patients with hip and knee arthroplasties. Acta Orthop Scand 2004; 75(2):173-176.
184. Nishimoto K, Yamamura K, Fukase F, Kobayashi M, Nishikimi N, Komori K. Subcutaneous tissue release of amikacin from a fibrin glue/polyurethane graft. J Infect Chemother 2004; 10(2):101-104.